Price T Rowe Associates Inc. MD lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 8.4% in the first quarter, Holdings Channel reports. The firm owned 1,322,454 shares of the medical research company’s stock after selling 120,721 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Charles River Laboratories International were worth $358,320,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of CRL. Blue Trust Inc. increased its stake in Charles River Laboratories International by 21.9% in the fourth quarter. Blue Trust Inc. now owns 985 shares of the medical research company’s stock valued at $233,000 after acquiring an additional 177 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Charles River Laboratories International by 5.7% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock worth $266,000 after buying an additional 61 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Charles River Laboratories International by 5.1% during the 4th quarter. Fifth Third Bancorp now owns 12,062 shares of the medical research company’s stock worth $2,851,000 after buying an additional 580 shares during the last quarter. Norris Perne & French LLP MI boosted its stake in Charles River Laboratories International by 27.1% in the fourth quarter. Norris Perne & French LLP MI now owns 131,993 shares of the medical research company’s stock valued at $31,203,000 after buying an additional 28,103 shares in the last quarter. Finally, DAVENPORT & Co LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at about $1,904,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.
Charles River Laboratories International Stock Up 5.3 %
CRL traded up $11.66 during midday trading on Friday, hitting $233.47. The company had a trading volume of 646,236 shares, compared to its average volume of 451,382. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The stock’s 50 day moving average price is $212.96 and its 200 day moving average price is $230.20. The company has a market capitalization of $12.03 billion, a price-to-earnings ratio of 27.47, a PEG ratio of 2.23 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating for the company in a report on Wednesday, July 10th. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. TD Cowen decreased their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research report on Monday, May 13th. Finally, Mizuho began coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 price target on the stock. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $252.29.
View Our Latest Research Report on Charles River Laboratories International
Insider Activity
In related news, EVP Joseph W. Laplume sold 1,304 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Recommended Stories
- Five stocks we like better than Charles River Laboratories International
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Why Call Options Volume for These 2 Stocks Spiked Together
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.